Androgen receptor

A complex therapeutic target for breast cancer

Ramesh Narayanan, James T. Dalton

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Molecular and histopathological profiling have classified breast cancer into multiple sub-types empowering precision treatment. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments. The high expression of AR in breast cancer and recent discovery and development of new nonsteroidal drugs targeting the AR provide a strong rationale for exploring it again as a therapeutic target in this disease. Ironically, both nonsteroidal agonists and antagonists for the AR are undergoing clinical trials, making AR a complicated target to understand in breast cancer. This review provides a detailed account of AR’s therapeutic role in breast cancer.

Original languageEnglish (US)
Article number108
JournalCancers
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Androgen Receptors
Breast Neoplasms
Androgen Receptor Antagonists
Therapeutics
Drug Delivery Systems
Epidermal Growth Factor Receptor
Estrogen Receptors
Androgens
Clinical Trials
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Androgen receptor : A complex therapeutic target for breast cancer. / Narayanan, Ramesh; Dalton, James T.

In: Cancers, Vol. 8, No. 12, 108, 01.12.2016.

Research output: Contribution to journalReview article

@article{53c86a02a5544c99affbaf7a6f8f4a26,
title = "Androgen receptor: A complex therapeutic target for breast cancer",
abstract = "Molecular and histopathological profiling have classified breast cancer into multiple sub-types empowering precision treatment. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments. The high expression of AR in breast cancer and recent discovery and development of new nonsteroidal drugs targeting the AR provide a strong rationale for exploring it again as a therapeutic target in this disease. Ironically, both nonsteroidal agonists and antagonists for the AR are undergoing clinical trials, making AR a complicated target to understand in breast cancer. This review provides a detailed account of AR’s therapeutic role in breast cancer.",
author = "Ramesh Narayanan and Dalton, {James T.}",
year = "2016",
month = "12",
day = "1",
doi = "10.3390/cancers8120108",
language = "English (US)",
volume = "8",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - Androgen receptor

T2 - A complex therapeutic target for breast cancer

AU - Narayanan, Ramesh

AU - Dalton, James T.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Molecular and histopathological profiling have classified breast cancer into multiple sub-types empowering precision treatment. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments. The high expression of AR in breast cancer and recent discovery and development of new nonsteroidal drugs targeting the AR provide a strong rationale for exploring it again as a therapeutic target in this disease. Ironically, both nonsteroidal agonists and antagonists for the AR are undergoing clinical trials, making AR a complicated target to understand in breast cancer. This review provides a detailed account of AR’s therapeutic role in breast cancer.

AB - Molecular and histopathological profiling have classified breast cancer into multiple sub-types empowering precision treatment. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments. The high expression of AR in breast cancer and recent discovery and development of new nonsteroidal drugs targeting the AR provide a strong rationale for exploring it again as a therapeutic target in this disease. Ironically, both nonsteroidal agonists and antagonists for the AR are undergoing clinical trials, making AR a complicated target to understand in breast cancer. This review provides a detailed account of AR’s therapeutic role in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85006013282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006013282&partnerID=8YFLogxK

U2 - 10.3390/cancers8120108

DO - 10.3390/cancers8120108

M3 - Review article

VL - 8

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 12

M1 - 108

ER -